Rocio Evangelista

Head, Preclinical Pharmacology Medical & Health Molecular Partners

Seminars

Wednesday 2nd December 2026
Insights Exchange – How Should Teams Select the Right Model Under Real World Constraints?
2:10 pm
  • What characteristics consistently appear in models that successfully predict patient outcomes?
  • Where do models most commonly fail despite encouraging preclinical data?
  • Which translational endpoints should teams prioritise when evaluating model performance
  • Audience Q&A
Wednesday 2nd December 2026
Evidence – Advancing the 3Rs Through Integrated Use of 3D Spheroids & In Vivo Models in Immuno-Oncology Development
1:00 pm
  • Evaluating how 3D spheroids and advanced in vitro systems can complement in vivo studies to improve biological relevance and reduce animal use
  • Determining which questions require complex in vivo models versus alternative approaches across different stages of development
  • Building robust preclinical evidence packages that balance translational confidence, operational feasibility, and 3Rs principles
Rocio Evangelista Vaz, Head of Preclinical Pharmacology at Molecular Partners AG, speaker at the 15th Tumour Models Summit London